Online citations, reference lists, and bibliographies.
← Back to Search

[Thrombolysis For Ischemic Stroke: An Update].

M. Koehrmann, E. Juettler, H. Huttner, P. D. Schellinger
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Even 10 years after the approval of thrombolysis this life-saving and disability reducing therapy is still underused. Important reasons for that are very strict inclusion criteria such as the early and narrow time-window, fear of bleeding complications and doubts regarding the effectiveness. An intensive and constant effort is required to educate the public that stroke is a treatable emergency. In addition to the medical reasons, economic considerations in a context of decreasing resources emphasize the importance of effective stroke treatment. The results of numerous recent studies such as the European register SITS-MOST help to strengthen the confidence in thrombolysis. In addition the development and advancement of new imaging tools such as multiparametric MRI and advanced CT-techniques will improve patient selection and may enable us to extend the time-window for treatment. Intraarterial thrombolysis, "bridging" methods and new devices for intravascular intervention are the subjects of intensive ongoing research. Even though no randomized trials are available intraarterial thrombolysis is the treatment of choice for acute basilar occlusion, but if this intervention is not available an intravenous approach may be an equal alternative.
This paper references
10.1001/JAMA.282.21.2019
Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
W. Clark (1999)
10.1161/01.STR.0000121641.77121.98
Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study
Ims Study Investigators (2004)
10.1007/BF00593977
Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA)
H. Zeumer (2004)
10.1212/WNL.56.8.1015
Why are stroke patients excluded from TPA therapy?
P. Barber (2001)
10.1161/01.STR.0000217403.66996.6d
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset
A. Furlan (2006)
10.1016/S0140-6736(98)08020-9
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
W. Hacke (1998)
10.1503/cmaj.1041561
Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study
M. Hill (2005)
10.1001/JAMA.282.21.2003
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.
A. Furlan (1999)
10.1161/01.STR.0000185696.73938.e0
Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis With Tissue Plasminogen Activator in Very Old (≥80 Years) Stroke Patients
J. Berrouschot (2005)
10.1161/01.STR.19.10.1216
Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease.
W. Hacke (1988)
10.1161/01.STR.0000170707.86793.1a
Transcranial Low-Frequency Ultrasound-Mediated Thrombolysis in Brain Ischemia: Increased Risk of Hemorrhage With Combined Ultrasound and Tissue Plasminogen Activator Results of a Phase II Clinical Trial
M. Daffertshofer (2005)
10.1161/01.STR.0000157668.39374.56
Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of a Randomized Phase 2 Trial
Abciximab Emergent Stroke Treatment Trial Investigators (2005)
10.1007/s00115-005-2047-x
Schlaganfallbehandlung im deutschen DRG-System 2006
N. Roeder (2005)
10.1212/01.wnl.0000183702.04080.27
Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis
S. Engelter (2005)
10.1212/WNL.58.3.474
Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban
U. Junghans (2002)
10.1212/WNL.50.4.883
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke
S. Fagan (1998)
10.1161/01.STR.0000030109.12281.23
Effect of Intravenous Thrombolysis on MRI Parameters and Functional Outcome in Acute Stroke <6 Hours
J. Roether (2002)
10.1097/00003246-200109000-00027
Thrombolytic therapy for ischemic stroke—A review. Part I—Intravenous thrombolysis
P. Schellinger (2001)
10.1001/JAMA.283.9.1145
Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
G. Albers (2000)
10.1136/jnnp.2004.049924
Outcome in patients with basilar artery occlusion treated conventionally
W. Schonewille (2005)
10.1097/00003246-200109000-00028
Thrombolytic therapy for ischemic stroke—A review. Part II—Intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging
P. Schellinger (2001)
10.1161/01.STR.29.1.4
PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
G. D. del Zoppo (1998)
10.1161/01.STR.0000199064.94588.39
Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator.
C. Molina (2006)
10.1161/01.STR.32.8.1832
Treatment With Tissue Plasminogen Activator and Inpatient Mortality Rates for Patients With Ischemic Stroke Treated in Community Hospitals
S. Reed (2001)
10.1161/01.STR.29.8.1544
Early intravenous thrombolysis for acute ischemic stroke in a community-based approach.
M. Grond (1998)
10.1161/01.STR.0000202582.29510.6b
Therapy of Basilar Artery Occlusion: A Systematic Analysis Comparing Intra-Arterial and Intravenous Thrombolysis
P. Lindsberg (2006)
10.1016/S1474-4422(06)70499-9
MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study
M. Koehrmann (2006)
10.1161/01.STR.0000149938.08731.2c
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase
W. Hacke (2005)
10.1159/000087204
Cost-Effectiveness Analysis of Thrombolytic Treatment for Stroke
J. Mar (2005)
10.1161/01.STR.0000204120.79399.72
Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials
G. Thomalla (2006)
10.1007/s001150170058
Thrombolyse bei zerebraler Ischämie Eine Übersicht
P. Schellinger (2001)
10.1056/NEJMOA052980
NXY-059 for acute ischemic stroke.
K. Lees (2006)
10.1056/NEJMOA041175
Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke.
A. Alexandrov (2004)
Thrombolyse bei zerebraler Ischämie
Peter D. Schellinger (2001)
10.1056/NEJM199512143332401
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
J. Grotta (1995)
10.1161/01.STR.0000140891.70547.56
Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial
T. Ingall (2004)
10.1093/AGEING/AFH065
Barriers to delivery of thrombolysis for acute stroke.
M. Barber (2004)
10.1161/01.STR.0000254580.39297.3c
Confirmation of tPA Treatment Effect by Baseline Severity-Adjusted End Point Reanalysis of the NINDS-tPA Stroke Trials
J. Saver (2007)
10.1016/S0140-6736(04)15692-4
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.
Ecass (2004)
10.1161/01.STR.0000199851.24668.F1
Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002.
B. Bateman (2006)
10.1161/01.STR.0000154872.73240.e9
A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke
E. Haley (2005)
10.1161/01.STR.19.7.802
Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery.
E. Mori (1988)
10.1212/WNL.53.1.3
CACNA1A mutations
E. Tournier-Lasserve (1999)
10.1161/01.STR.0000165918.80812.1e
Aggressive Therapy With Intravenous Abciximab and Intra-Arterial rtPA and Additional PTA/Stenting Improves Clinical Outcome in Acute Vertebrobasilar Occlusion: Combined Local Fibrinolysis and Intravenous Abciximab in Acute Vertebrobasilar Stroke Treatment (FAST) Results of a Multicenter Study
B. Eckert (2005)
10.1161/01.STR.30.12.2598
Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.
C. Lewandowski (1999)
10.1001/JAMA.1995.03530130023023
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
W. Hacke (1995)
10.1159/000086121
Results of a Multicentre, Randomised Controlled Trial of Intra-Arterial Urokinase in the Treatment of Acute Posterior Circulation Ischaemic Stroke
M. Macleod (2005)
10.1161/01.STR.0000202591.18871.F7
A Pilot Study of a New Thrombolytic Agent for Acute Ischemic Stroke in Taiwan Within A Five-Hour Window
Han-Hwa Hu (2006)
10.1001/JAMA.292.15.1862
Long-term outcome after intravenous thrombolysis of basilar artery occlusion.
P. Lindsberg (2004)
Thrombolysis in acute ischemic stroke: controlled trials and clinical experience.
W. Hacke (1999)
10.1159/000108174
Thrombolysis in the Vertebrobasilar Circulation: The Australian Urokinase Stroke Trial
P. Mitchell (1997)



This paper is referenced by
10.1007/S00390-009-0117-1
Prähospitalversorgung und Akuttherapie des ischämischen Schlaganfalls
M Koehrmann (2010)
10.1177/0883073808319076
Use of Intravenous Tissue Plasminogen Activator in a 16-Year-Old Patient with Basilar Occlusion
Jason W Heil (2008)
10.1177/1591019918774761
Successful thrombectomy in endocarditis-related stroke: Case report and review of the literature
Manuel Bolognese (2018)
Studies on spreading depolarization in healthy and metabolically compromised brain tissues
I. Aiba (2012)
10.1177/0883073811408091
Potential Eligibility for Recombinant Tissue Plasminogen Activator Therapy in Children: A Population-Based Study
Laura L. Lehman (2011)
10.1097/PEC.0000000000000436
Pediatric Acute Ischemic Cerebral Vascular Accidents: A Case Report
S. Lahham (2017)
10.1007/s10753-020-01212-1
lncRNA ZFAS1 Improves Neuronal Injury and Inhibits Inflammation, Oxidative Stress, and Apoptosis by Sponging miR-582 and Upregulating NOS3 Expression in Cerebral Ischemia/Reperfusion Injury
Yanyan Zhang (2020)
10.1038/jcbfm.2010.5
Use of Magnetic Resonance Imaging to Predict Outcome after Stroke: A Review of Experimental and Clinical Evidence
T. Farr (2010)
10.1007/s11428-008-0258-z
Der Schlaganfall beim Diabetespatienten
J. Heckmann (2008)
10.17169/REFUBIUM-7373
Langzeitverlauf von Patienten mit ischämischem Schlaganfall nach systemischer Lysetherapie
Boris Dimitrijeski (2011)
Thrombolytic Use in Acute Ischemic Stroke Patients with Concurrent Infective Endocarditis : Emphasis on History , Physical Exam , Outcomes , and Review of Literature
Muhammad Shah Miran (2017)
Clinical outcome in ischemic stroke patients with hyperglycemia
A. A. Rahim (2018)
Rocco et al HbA 1 c and Hemorrhage After Thrombolysis in Stroke 2135 Patients and Methods Diagnostic and Treatment Protocol
A. Rocco ()
10.1016/j.neurad.2013.04.002
Evaluation of the ischemic penumbra focusing on the venous drainage: the role of susceptibility weighted imaging (SWI) in pediatric ischemic cerebral stroke.
A. Meoded (2014)
10.1016/j.jstrokecerebrovasdis.2015.12.004
Catastrophic Intracranial Hemorrhages after IV tPA in a Patient with Insidious Onset of Fever and Back Pain.
Steven Tversky (2016)
Comparative Evaluation of Diabetic and Non-Diabetic Stroke and the Study of Effect of Glycemic Levels on the Outcome of Stroke
D. Mahalakshmi (2019)
10.1007/s00062-011-0122-1
Neurointerventional Treatment of Amphetamine-Induced Acute Occlusion of the Middle Cerebral Artery by Intracranial Balloon Angioplasty
Björn Loewenhardt (2011)
10.1152/ajpregu.00256.2010
Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.
W. Armstead (2010)
10.1007/s11910-019-0935-x
Neurological Complications of Infective Endocarditis
Filipa Dourado Sotero (2019)
Accidentes cerebrovasculares en el niño y en el adolescente
P. Castro (2008)
10.1017/S1481803500010824
Successful treatment of pediatric stroke with recombinant tissue plasminogen activator (rt-PA): a case report and review of the literature.
S. Cremer (2008)
10.1016/j.ajem.2015.06.053
The infected heart: ventriculoseptal abscess and intracardiac fistulization.
K. Habeeb (2016)
10.4997/JRCPE.2015.316
Stigmata of infective endocarditis should be included in the compilation of the risk score.
O. Jolobe (2015)
10.1093/cid/cix1000
Mechanical Thrombectomy for Acute Ischemic Stroke Secondary to Infective Endocarditis
J. Ambrosioni (2018)
10.1586/14737175.2014.884927
The prospects and predicaments of intravenous rt-PA in childhood ischemic stroke
R. Behrouz (2014)
10.1007/s12975-011-0105-1
RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothrombosis
W. Armstead (2011)
10.1161/STROKEAHA.111.675918
Glycosylated Hemoglobin A1 Predicts Risk for Symptomatic Hemorrhage After Thrombolysis for Acute Stroke
A. Rocco (2013)
Guideline on Prevention and Treatment of Infective Endocarditis
S. Nakatani (2019)
10.1007/s00330-009-1390-x
Penumbra Stroke System as an “add-on” for the treatment of large vessel occlusive disease following thrombolysis: first results
T. Struffert (2009)
10.1007/s10049-008-1043-7
Update Thrombolyse des akuten ischämischen Schlaganfalls
M. Siebler (2008)
10.1161/STROKEAHA.108.529560
Thrombolysis in Childhood Stroke: Report of 2 Cases and Review of the Literature
M. Arnold (2009)
Semantic Scholar Logo Some data provided by SemanticScholar